Hanson & Doremus Investment Management’s Regeneron Pharmaceuticals REGN Stock Holding History

Hanson & Doremus Investment Management’s Portfolio REGN Stock Details REGN Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q2	$10K	Hold	16	–	–	﹤0.01%	440
2026 Q1	$12K	Hold	16	–	–	﹤0.01%	451
2025 Q4	$12K	Hold	16	–	–	﹤0.01%	428
2025 Q3	$9K	Buy	+16	New	+$9.05K	﹤0.01%	451
2024 Q3	–	Sell	-30	Closed	-$32K	–	444
2024 Q2	$32K	Hold	30	–	–	0.01%	335
2024 Q1	$29K	Hold	30	–	–	0.01%	342
2023 Q4	$26K	Hold	30	–	–	﹤0.01%	346
2023 Q3	$25K	Hold	30	–	–	0.01%	340
2023 Q2	$22K	Hold	30	–	–	﹤0.01%	357
2023 Q1	$25K	Hold	30	–	–	0.01%	352
2022 Q4	$22K	Hold	30	–	–	﹤0.01%	391
2022 Q3	$21K	Buy	+30	New	+$18.9K	0.01%	378
2022 Q1	–	Sell	-1	Closed	-$1K	–	531
2021 Q4	$1K	Hold	1	–	–	﹤0.01%	491
2021 Q3	$1K	Buy	+1	New	+$621	﹤0.01%	483
2021 Q2	–	Sell	-1	Closed	–	–	500
2021 Q1	$0	Buy	+1	New	+$487	﹤0.01%	532

Other funds holding REGN

BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return

Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM

Dodge & Cox San Francisco, California $191B AUM 17.5% 1-Year Est. Return

State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return

Invesco Atlanta, Georgia $1.26T AUM 61.52% 1-Year Est. Return

JP Morgan Chase New York $1.81T AUM 41.13% 1-Year Est. Return

Vanguard Portfolio Management Malvern, Pennsylvania $2.22T AUM

Franklin Resources San Mateo, California $462B AUM 39.16% 1-Year Est. Return

Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return

Nuveen Charlotte, North Carolina $419B AUM 43.02% 1-Year Est. Return

Hanson & Doremus Investment Management's REGN Position: Q2 2026 in Review

Hanson & Doremus Investment Management held its Regeneron Pharmaceuticals (REGN) position steady in Q2 2026 at 16 shares worth $10K. The position accounts for ﹤0.01% of the portfolio, ranked #440.

Hanson & Doremus Investment Management first reported a position in REGN in Q1 2021 and has held it in 15 quarters since. The position peaked at $32K in Q2 2024. 1,333 funds tracked by Wall St. Rank hold REGN as of Q2 2026.

Hanson & Doremus Investment Management held 16 shares of Regeneron Pharmaceuticals worth $10K as of Q2 2026.
Hanson & Doremus Investment Management left its Regeneron Pharmaceuticals share count unchanged in Q2 2026.
Regeneron Pharmaceuticals made up ﹤0.01% of Hanson & Doremus Investment Management's portfolio in Q2 2026, its #440 holding.
Hanson & Doremus Investment Management first reported a position in Regeneron Pharmaceuticals in Q1 2021 and has held it in 15 quarters since.
Hanson & Doremus Investment Management's Regeneron Pharmaceuticals position peaked at $32K in Q2 2024.
1,333 funds tracked by Wall St. Rank held Regeneron Pharmaceuticals as of Q2 2026.

Based on Hanson & Doremus Investment Management's 13F filing for Q2 2026, filed 29 Jul 2026.